LIVIVO - Search results -

Search results

Result 1 - 10 of total 149

Search options

Article ; Online: Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.

Schiff, Michael H

2013 Volume 65, Issue 11, Page(s) 1892

MeSH term(s)	Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/therapy ; Choice Behavior ; Humans ; Patient Participation ; Physicians/standards ; Rheumatology/standards
Language	English
Publishing date	2013-11
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
DOI	10.1002/acr.22076
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.

Schiff, Michael H

Arthritis care & research

2013 Volume 65, Issue 11, Page(s) 1892

MeSH term(s)	Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/therapy ; Choice Behavior ; Humans ; Patient Participation ; Physicians/standards ; Rheumatology/standards
Language	English
Publishing date	2013-11
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.

Schiff, Michael H / Sadowski, Peter

Rheumatology international

2017 Volume 37, Issue 2, Page(s) 213–218

Abstract: Both the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines recommend the use of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA) when there is no contraindication. While MTX is the ... ...

Abstract	Both the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines recommend the use of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA) when there is no contraindication. While MTX is the foundation of RA therapy (Singh et al. in Arthritis Care Res 64:625-639,2012), absorption saturation compromises its oral bioavailability (BA). Differences in the relative BA of oral versus subcutaneous (SC) MTX demonstrate the need for guidance on successful dose-conversion strategies. This study was designed to compare MTX PK profiles as a result of MTX administration via three different treatment administrations: oral, SC MTX administered via an auto-injector (MTXAI) into the abdomen (MTXAI
MeSH term(s)	Administration, Oral ; Aged ; Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Injections, Subcutaneous ; Male ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use ; Middle Aged ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2017-02
Publishing country	Germany
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	8286-7
ISSN	1437-160X ; 0172-8172
ISSN (online)	1437-160X
ISSN	0172-8172
DOI	10.1007/s00296-016-3621-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1639: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Feasibility of surface-guidance combined with CBCT for intra-fractional breath-hold motion management during Ethos RT.

Kim, Taeho / Laugeman, Eric / Kiser, Kendall / Schiff, Joshua / Marasini, Shanti / Price, Alex / Gach, H Michael / Knutson, Nels / Samson, Pamela / Robinson, Clifford / Hatscher, Casey / Henke, Lauren

Journal of applied clinical medical physics

2024 Volume 25, Issue 4, Page(s) e14242

Abstract: Purpose: High-quality CBCT and AI-enhanced adaptive planning techniques allow CBCT-guided stereotactic adaptive radiotherapy (CT-STAR) to account for inter-fractional anatomic changes. Studies of intra-fractional respiratory motion management with a ... ...

Abstract	Purpose: High-quality CBCT and AI-enhanced adaptive planning techniques allow CBCT-guided stereotactic adaptive radiotherapy (CT-STAR) to account for inter-fractional anatomic changes. Studies of intra-fractional respiratory motion management with a surface imaging solution for CT-STAR have not been fully conducted. We investigated intra-fractional motion management in breath-hold Ethos-based CT-STAR and CT-SBRT (stereotactic body non-adaptive radiotherapy) using optical surface imaging combined with onboard CBCTs. Methods: Ten cancer patients with mobile lower lung or upper abdominal malignancies participated in an IRB-approved clinical trial (Phase I) of optical surface image-guided Ethos CT-STAR/SBRT. In the clinical trial, a pre-configured gating window (± 2 mm in AP direction) on optical surface imaging was used for manually triggering intra-fractional CBCT acquisition and treatment beam irradiation during breath-hold (seven patients for the end of exhalation and three patients for the end of inhalation). Two inter-fractional CBCTs at the ends of exhalation and inhalation in each fraction were acquired to verify the primary direction and range of the tumor/imaging-surrogate (donut-shaped fiducial) motion. Intra-fractional CBCTs were used to quantify the residual motion of the tumor/imaging-surrogate within the pre-configured breath-hold window in the AP direction. Fifty fractions of Ethos RT were delivered under surface image-guidance: Thirty-two fractions with CT-STAR (adaptive RT) and 18 fractions with CT-SBRT (non-adaptive RT). The residual motion of the tumor was quantified by determining variations in the tumor centroid position. The dosimetric impact on target coverage was calculated based on the residual motion. Results: We used 46 fractions for the analysis of intra-fractional residual motion and 43 fractions for the inter-fractional motion analysis due to study constraints. Using the image registration method, 43 pairs of inter-fractional CBCTs and 100 intra-fractional CBCTs attached to dose maps were analyzed. In the motion range study (image registration) from the inter-fractional CBCTs, the primary motion (mean ± std) was 16.6 ± 9.2 mm in the SI direction (magnitude: 26.4 ± 11.3 mm) for the tumors and 15.5 ± 7.3 mm in the AP direction (magnitude: 20.4 ± 7.0 mm) for the imaging-surrogate, respectively. The residual motion of the tumor (image registration) from intra-fractional breath-hold CBCTs was 2.2 ± 2.0 mm for SI, 1.4 ± 1.4 mm for RL, and 1.3 ± 1.3 mm for AP directions (magnitude: 3.5 ± 2.1 mm). The ratio of the actual dose coverage to 99%, 90%, and 50% of the target volume decreased by 0.95 ± 0.11, 0.96 ± 0.10, 0.99 ± 0.05, respectively. The mean percentage of the target volume covered by the prescribed dose decreased by 2.8 ± 4.4%. Conclusion: We demonstrated the intra-fractional motion-managed treatment strategy in breath-hold Ethos CT-STAR/SBRT using optical surface imaging and CBCT. While the controlled residual tumor motion measured at 3.5 mm exceeded the predetermined setup value of 2 mm, it is important to note that this motion still fell within the clinically acceptable range defined by the PTV margin of 5 mm. Nonetheless, additional caution is needed with intra-fractional motion management in breath-hold Ethos CT-STAR/SBRT using optical surface imaging and CBCT.
MeSH term(s)	Humans ; Breath Holding ; Cone-Beam Computed Tomography/methods ; Feasibility Studies ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/radiotherapy ; Lung Neoplasms/pathology ; Radiosurgery/methods ; Radiotherapy Planning, Computer-Assisted/methods ; Radiotherapy, Image-Guided/methods ; Spiral Cone-Beam Computed Tomography
Language	English
Publishing date	2024-01-04
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	2010347-5
ISSN	1526-9914 ; 1526-9914
ISSN (online)	1526-9914
ISSN	1526-9914
DOI	10.1002/acm2.14242
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Integrated plasma proteomics identifies tuberculosis-specific diagnostic biomarkers.

Schiff, Hannah F / Walker, Naomi F / Ugarte-Gil, Cesar / Tebruegge, Marc / Manousopoulou, Antigoni / Garbis, Spiros D / Mansour, Salah / Wong, Pak Ho Michael / Rockett, Gabrielle / Piazza, Paolo / Niranjan, Mahesan / Vallejo, Andres F / Woelk, Christopher H / Wilkinson, Robert J / Tezera, Liku B / Garay-Baquero, Diana / Elkington, Paul

JCI insight

2024 Volume 9, Issue 8

Abstract: BACKGROUNDNovel biomarkers to identify infectious patients transmitting Mycobacterium tuberculosis are urgently needed to control the global tuberculosis (TB) pandemic. We hypothesized that proteins released into the plasma in active pulmonary TB are ... ...

Abstract	BACKGROUNDNovel biomarkers to identify infectious patients transmitting Mycobacterium tuberculosis are urgently needed to control the global tuberculosis (TB) pandemic. We hypothesized that proteins released into the plasma in active pulmonary TB are clinically useful biomarkers to distinguish TB cases from healthy individuals and patients with other respiratory infections.METHODSWe applied a highly sensitive non-depletion tandem mass spectrometry discovery approach to investigate plasma protein expression in pulmonary TB cases compared to healthy controls in South African and Peruvian cohorts. Bioinformatic analysis using linear modeling and network correlation analyses identified 118 differentially expressed proteins, significant through 3 complementary analytical pipelines. Candidate biomarkers were subsequently analyzed in 2 validation cohorts of differing ethnicity using antibody-based proximity extension assays.RESULTSTB-specific host biomarkers were confirmed. A 6-protein diagnostic panel, comprising FETUB, FCGR3B, LRG1, SELL, CD14, and ADA2, differentiated patients with pulmonary TB from healthy controls and patients with other respiratory infections with high sensitivity and specificity in both cohorts.CONCLUSIONThis biomarker panel exceeds the World Health Organization Target Product Profile specificity criteria for a triage test for TB. The new biomarkers have potential for further development as near-patient TB screening assays, thereby helping to close the case-detection gap that fuels the global pandemic.FUNDINGMedical Research Council (MRC) (MR/R001065/1, MR/S024220/1, MR/P023754/1, and MR/W025728/1); the MRC and the UK Foreign Commonwealth and Development Office; the UK National Institute for Health Research (NIHR); the Wellcome Trust (094000, 203135, and CC2112); Starter Grant for Clinical Lecturers (Academy of Medical Sciences UK); the British Infection Association; the Program for Advanced Research Capacities for AIDS in Peru at Universidad Peruana Cayetano Heredia (D43TW00976301) from the Fogarty International Center at the US NIH; the UK Technology Strategy Board/Innovate UK (101556); the Francis Crick Institute, which receives funding from UKRI-MRC (CC2112); Cancer Research UK (CC2112); and the NIHR Biomedical Research Centre of Imperial College NHS.
MeSH term(s)	Humans ; Biomarkers/blood ; Proteomics/methods ; Male ; Female ; Adult ; Tuberculosis, Pulmonary/diagnosis ; Tuberculosis, Pulmonary/blood ; Mycobacterium tuberculosis ; Middle Aged ; Peru/epidemiology ; South Africa/epidemiology ; Case-Control Studies ; Sensitivity and Specificity
Chemical Substances	Biomarkers
Language	English
Publishing date	2024-03-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ISSN	2379-3708
ISSN (online)	2379-3708
DOI	10.1172/jci.insight.173273
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials.

Buch, Maya H / Johnsen, Alyssa / Schiff, Michael

Clinical and experimental rheumatology

2018 Volume 37, Issue 1, Page(s) 127–132

Abstract: Objectives: To explore antinuclear autoantibody (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibody development during abatacept and tumour necrosis factor inhibitor (TNFi) treatment, and effects of switching from TNFi to abatacept in ANA/anti- ... ...

Abstract	Objectives: To explore antinuclear autoantibody (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibody development during abatacept and tumour necrosis factor inhibitor (TNFi) treatment, and effects of switching from TNFi to abatacept in ANA/anti-dsDNA autoantibody-positive patients. Methods: This was a post hoc analysis of biologic-naïve patients with active RA in ATTEST and AMPLE. In AMPLE, patients received subcutaneous abatacept or adalimumab (2 years). In ATTEST, patients received intravenous abatacept or infliximab (1 year), or placebo (6 months) then abatacept (6 months); at 1 year, all patients could receive abatacept (open-label long-term extension). Serum ANA/anti-dsDNA autoantibody levels were measured at baseline, Month 6 (ATTEST only), Years 1 and 2. Results: At baseline, 25.7 and 0.9% (AMPLE), and 21.6 and 8.4% of patients (ATTEST) were ANA/anti-dsDNA autoantibody positive, respectively. More baseline ANA/anti-dsDNA autoantibody-negative patients became positive during TNFi than abatacept treatment. In ATTEST (TNFi group), 48.5% (48/99; ANA) and 48.3% (57/118; anti-dsDNA) of patients seroconverted to positive status by Year 1, falling to 22.4% (22/98 ANA) and 13.3% (15/113; anti-dsDNA) by Year 2 after switching to abatacept. Of ANA/anti-dsDNA autoantibody-positive patients at Year 1, 41.9% and 68.9%, were negative at Year 2. Conclusions: ANA/anti-dsDNA seroconversion was more frequent with TNFi than abatacept therapy; TNFi-associated seroconversion decreased after switching from TNFi to abatacept.
MeSH term(s)	Abatacept/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; DNA/analysis ; Humans ; Infliximab ; Methotrexate/therapeutic use ; Treatment Failure ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Antibodies, Monoclonal ; Antirheumatic Agents ; Tumor Necrosis Factor-alpha ; Abatacept (7D0YB67S97) ; DNA (9007-49-2) ; Infliximab (B72HH48FLU) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2018-08-21
Publishing country	Italy
Document type	Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications.

Schiff, Michael H

The American journal of managed care

2010 Volume 16, Issue 9 Suppl, Page(s) S243–8

Abstract: A significant percentage of patients presenting with undifferentiated arthritis (UA) will progress to rheumatoid arthritis (RA), while others will undergo spontaneous remission. Evidence supports the use of therapeutic intervention in patients with UA to ...

Abstract	A significant percentage of patients presenting with undifferentiated arthritis (UA) will progress to rheumatoid arthritis (RA), while others will undergo spontaneous remission. Evidence supports the use of therapeutic intervention in patients with UA to delay or halt disease progression and its long-term consequences. However, there is first a need to screen patients with UA to identify those with a high probability of progressing to RA who would benefit from antirheumatic therapy. The 2010 American College of Rheumatology/European League Against Rheumatism RA classification criteria were designed for this purpose. These criteria can aid clinicians in deciding when it is appropriate to initiate therapy in patients at risk of progressing to RA. These criteria can also have important implications in reducing the inappropriate and unnecessary use of antirheumatic agents in patients less likely to develop RA, thus reducing healthcare costs and minimizing the risk of sequelae associated with these agents. Use of disease-modifying antirheumatic drugs and biologic agents in patients with UA has been associated with delays in disease progression. However, further clinical studies are needed to fully evaluate the long-term clinical and economic outcomes of these agents in patients with UA.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis/diagnosis ; Arthritis/drug therapy ; Arthritis/physiopathology ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/prevention & control ; Cost-Benefit Analysis ; Disease Progression ; Humans ; Mass Screening/methods
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2010-11
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2035781-3
ISSN	1936-2692 ; 1088-0224 ; 1096-1860
ISSN (online)	1936-2692
ISSN	1088-0224 ; 1096-1860
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5353: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 86: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.

Jabado, Omar / Maldonado, Michael A / Schiff, Michael / Weinblatt, Michael E / Fleischmann, Roy / Robinson, William H / He, Aiqing / Patel, Vishal / Greenfield, Alex / Saini, Jasmine / Galbraith, David / Connolly, Sean E

Rheumatology and therapy

2021 Volume 9, Issue 2, Page(s) 391–409

Abstract: Introduction: The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on ...

Abstract	Introduction: The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on anti-citrullinated protein antibodies (ACPAs) and gene expression. Methods: AMPLE was a phase IIIb, 2-year, randomized, head-to-head trial of abatacept versus adalimumab. Post hoc analyses of baseline anti-cyclic citrullinated peptide-2 (anti-CCP2, an ACPA surrogate) positive (+) status and ACPA fine-specificity profiles over time, as well as transcriptional profiling (peripheral whole blood), were performed. Results: Of 646 patients treated (abatacept, n = 318; adalimumab, n = 328), ACPA and gene expression data were available from 508 and 566 patients, respectively. In anti-CCP2+ patients (n = 388), baseline fine specificities for most ACPAs were highly correlated; over 2 years, levels decreased with abatacept but not adalimumab. By year 2, expression of genes associated with T cell co-stimulation and antibody production was lower for abatacept versus adalimumab; expression of genes associated with proinflammatory signaling was lower for adalimumab versus abatacept. Treatment modulated the expression of T- and B-cell gene signatures, with differences in CD8+ T cells, activated T cells, plasma cells, B cells, natural killer cells (all lower with abatacept versus adalimumab), and polymorphonuclear leukocytes (higher with abatacept versus adalimumab). Conclusions: In AMPLE, despite similar clinical outcomes, data showed that pharmacodynamic/genetic changes after 2 years of abatacept or adalimumab were consistent with drug MoAs. Further assessment of the relationship between such changes and clinical outcomes, including prediction of response, is warranted. Trial registration: ClinicalTrials.gov identifier, NCT00929864.
Language	English
Publishing date	2021-12-08
Publishing country	England
Document type	Journal Article
ZDB-ID	2783278-8
ISSN	2198-6584 ; 2198-6576
ISSN (online)	2198-6584
ISSN	2198-6576
DOI	10.1007/s40744-021-00404-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment.

Gundle, Kenneth R / Rajasekaran, Karthik / Houlton, Jeffrey / Deutsch, Gary B / Ow, Thomas J / Maki, Robert G / Pang, John / Nathan, Cherie-Ann O / Clayburgh, Daniel / Newman, Jason G / Brinkmann, Elyse / Wagner, Michael J / Pollack, Seth M / Thompson, Matthew J / Li, Ryan J / Mehta, Vikas / Schiff, Bradley A / Wenig, Barry I / Swiecicki, Paul L /

Tang, Alice L / Davis, Jessica L / van Zante, Annemieke / Bertout, Jessica A / Jenkins, Wendy / Turner, Atticus / Grenley, Marc / Burns, Connor / Frazier, Jason P / Merrell, Angela / Sottero, Kimberly H W / Derry, Jonathan M J / Gillespie, Kate C / Mills, Bre / Klinghoffer, Richard A

Frontiers in pharmacology

2024 Volume 15, Page(s) 1367581

Abstract: Introduction: ...

Abstract	Introduction:
Language	English
Publishing date	2024-04-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2024.1367581
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.

Schiff, Michael H

Arthritis and rheumatism

2005 Volume 52, Issue 1, Page(s) 364–5; author reply 365

MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Humans ; Interleukin 1 Receptor Antagonist Protein ; Sialoglycoproteins/therapeutic use ; Treatment Failure ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Antirheumatic Agents ; IL1RN protein, human ; Interleukin 1 Receptor Antagonist Protein ; Sialoglycoproteins ; Tumor Necrosis Factor-alpha
Language	English
Publishing date	2005-01
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	127294-9
ISSN	1529-0131 ; 0004-3591 ; 2326-5191
ISSN (online)	1529-0131
ISSN	0004-3591 ; 2326-5191
DOI	10.1002/art.20769
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 523: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito